114 related articles for article (PubMed ID: 16640659)
21. A study of the xenoantigenicity of neonatal porcine islet-like cell clusters (NPCC) and the efficiency of adenovirus-mediated DAF (CD55) expression.
Omori T; Nishida T; Komoda H; Fumimoto Y; Ito T; Sawa Y; Gao C; Nakatsu S; Shirakura R; Miyagawa S
Xenotransplantation; 2006 Sep; 13(5):455-64. PubMed ID: 16925670
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.
Suzuki M; Kato-Nakano M; Kawamoto S; Furuya A; Abe Y; Misaka H; Kimoto N; Nakamura K; Ohta S; Ando H
Cancer Sci; 2009 Sep; 100(9):1623-30. PubMed ID: 19555390
[TBL] [Abstract][Full Text] [Related]
23. Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas.
Ravindranath NM; Shuler C
J Oral Pathol Med; 2006 Oct; 35(9):560-7. PubMed ID: 16968237
[TBL] [Abstract][Full Text] [Related]
24. Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor.
Modak S; Gerald W; Cheung NK
Med Pediatr Oncol; 2002 Dec; 39(6):547-51. PubMed ID: 12376975
[TBL] [Abstract][Full Text] [Related]
25. Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55.
Li B; Allendorf DJ; Hansen R; Marroquin J; Cramer DE; Harris CL; Yan J
Cancer Res; 2007 Aug; 67(15):7421-30. PubMed ID: 17671212
[TBL] [Abstract][Full Text] [Related]
26. Peritoneal mesothelial cells produce complement factors and express CD59 that inhibits C5b-9-mediated cell lysis.
Barbano G; Cappa F; Prigione I; Tedesco F; Pausa M; Gugliemino R; Pistoia V; Gusmano R; Perfumo F
Adv Perit Dial; 1999; 15():253-7. PubMed ID: 10682113
[TBL] [Abstract][Full Text] [Related]
27. Expression of complement system regulatory molecules in the endometrium of normal ovulatory and hyperstimulated women correlate with menstrual cycle phase.
Nogawa Fonzar-Marana RR; Ferriani RA; Soares SG; Cavalcante-Neto FF; Teixeira JE; Barbosa JE
Fertil Steril; 2006 Sep; 86(3):758-61. PubMed ID: 16831436
[TBL] [Abstract][Full Text] [Related]
28. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
Aggarwal S; He T; Fitzhugh W; Rosenthal K; Feild B; Heidbrink J; Mesmer D; Ruben SM; Moore PA
Gynecol Oncol; 2009 Dec; 115(3):430-7. PubMed ID: 19800108
[TBL] [Abstract][Full Text] [Related]
29. Effect of tandem forms of DAF(CD55) on complement-mediated xenogeneic cell lysis.
Miyagawa S; Fukuta D; Kitano E; Kobayashi C; Fumimoto Y; Shirasu A; Hattori H; Shirakura R; Fukuzawa M
Xenotransplantation; 2006 Sep; 13(5):433-9. PubMed ID: 16925667
[TBL] [Abstract][Full Text] [Related]
30. Human DAF on pig cells protects against human and non-human primate sera cytotoxicity mediated by exogenous or endogenous complement, as determined by flow cytometry.
Díaz-Román TM; Mañez R; López-Pelaez E; Centeno A; Moscoso I; Pértegaz S; Doménech N
Transpl Immunol; 2006 Aug; 16(2):125-30. PubMed ID: 16860716
[TBL] [Abstract][Full Text] [Related]
31. Drug-resistance associated alterations of cell surface antigen expression in a human anthracycline-resistant ovarian carcinoma cell line.
Sedlák J; McGown A; Hrubisko M; Hunáková L; Chorváth B
Neoplasma; 1994; 41(5):259-62. PubMed ID: 7854495
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
33. Expression of complement regulatory proteins on human natural killer cell subsets.
Wang L; Halliday D; Johnson PM; Christmas SE
Immunol Lett; 2007 Oct; 112(2):104-9. PubMed ID: 17719652
[TBL] [Abstract][Full Text] [Related]
34. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
[TBL] [Abstract][Full Text] [Related]
35. Cell-mediated immunity and blocking factor in ovarian carcinoma.
Mitchell MS; Kohorn EI
Obstet Gynecol; 1976 Nov; 48(5):590-7. PubMed ID: 980285
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemically detecting target antigens in patient biopsies for tailoring monoclonal antibody based cancer therapy.
Smith NL; Finley JL; Wennerberg AE; Semer DA; Kearse KP
Hum Antibodies; 1999; 9(1):61-5. PubMed ID: 10331187
[TBL] [Abstract][Full Text] [Related]
37. [*OPCML gene transferred by recombinant lentiviruses in vitro and its inhibition to ovarian cancer cells].
Yao DS; Li L; Garson K; Vanderhyden BC
Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):333-8. PubMed ID: 16762191
[TBL] [Abstract][Full Text] [Related]
38. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.
Livingston PO; Hood C; Krug LM; Warren N; Kris MG; Brezicka T; Ragupathi G
Cancer Immunol Immunother; 2005 Oct; 54(10):1018-25. PubMed ID: 15926079
[TBL] [Abstract][Full Text] [Related]
39. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
40. Antitumor effect of antibody against a SEREX-defined antigen (UOEH-LC-1) on lung cancer xenotransplanted into severe combined immunodeficiency mice.
Mizukami M; Hanagiri T; Yasuda M; Kuroda K; Shigematsu Y; Baba T; Fukuyama T; Nagata Y; So T; Ichiki Y; Sugaya M; So T; Takenoyama M; Sugio K; Yasumoto K
Cancer Res; 2007 Sep; 67(17):8351-7. PubMed ID: 17804751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]